** Research analysts at investment banks that worked on Hinge Health's HNGE.N May IPO overwhelmingly bullish after quiet period ends
** Shares of San Francisco-based telehealth startup, which provides physical therapy services, closed at $34.85 on Fri, 9% above their $32 IPO price
** HNGE stock up 4% at $36.25 in very thin premarket trading
** Morgan Stanley, one of the IPO's lead bookrunners, initiates at 'overweight' saying HNGE is a "category leader in virtual musculoskeletal care with a highly scalable, differentiated AI-driven platform" and is selling into a $27 bln "serviceable available market" $(SAM)$
** Needham initiates at 'buy' saying MSK (musculoskeletal) category represents a "massive opportunity" in the U.S. as 40% of Americans have an MSK issue but only 9% currently receive treatment
** KeyBanc starts at 'overweight' pointing to key catalysts for the stock being co's "unique and proprietary technology" allowing seamless user experience, strong health plan network, growth supported by shift to utilitization-based pricing model, and margin expansion opportunities to approach longer-term goal of ~25% sooner than expected
CURRENT COVERAGE ACCORDING TO LSEG DATA (sorted by PT, descending order):
Brokerage | Rating | Price Target |
Outperform | $50 | |
Truist Secs | Buy | $48 |
Stifel | Buy | $48 |
Needham | Buy | $47 |
Overweight | $46 | |
Raymond James | Outperform | $45 |
KeyBanc | Overweight | $45 |
RBC | Outperform | $45 |
Barclays | Overweight | $43 |
Piper Sandler | Overweight | $41 |
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。